Huang, Chu-Ying <br/><br/>
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.  [electronic resource] 

 -  Oncotarget  Oct 2016 
 - 66480-66490 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.5515  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bone Neoplasms--drug therapy<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Crown Ethers--administration & dosage<br/>Diphosphonates--administration & dosage<br/>Disease-Free Survival<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride--administration & dosage<br/>Female<br/>Gefitinib<br/>Humans<br/>Imidazoles--administration & dosage<br/>Kaplan-Meier Estimate<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Pamidronate<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinazolines--administration & dosage<br/>Retrospective Studies<br/>Treatment Outcome<br/>Zoledronic Acid